In a single-center, retrospective analysis, echocardiography demonstrated low sensitivity but high specificity for diagnosing pulmonary hypertension (PH) in advanced chronic obstructive pulmonary disease (COPD).
Echocardiography has high specificity in the diagnosis of pulmonary hypertension (PH) in patients with advanced chronic obstructive pulmonary disease (COPD); however, it has low specificity for detecting PH in these patients, according to a recent study published in The American Journal of the Medical Sciences.
Detecting PH in patients with COPD is critical. Patients with COPD combined with PH carry increased risks for hospitalizations, mortality, and other exacerbations, and their PH status can influence candidacy for lung transplantation.
Right heart catheterization (RHC) is the typical approach for diagnosing PH, but the use of echocardiography could provide lots of benefits to patients. Comparatively, echocardiography is less expensive and invasive, and performs well in screening a patient’s pulmonary arterial pressure (PAP); however, the efficacy of this approach in identifying PH in patients with COPD is not sufficiently studied. Furthermore, at present RHC is relied upon for multiple transplant criteria including the management of transplant listing, identification and treatment of left-sided heart disease, as well as decision-making for single or double lung transplants. To address this gap, researchers conducted a study to evaluate the usefulness of echocardiography as a less-invasive diagnostic tool for PH in patients with COPD.
Patients with COPD being assessed for lung transplantation who also underwent RHC for PH diagnosis were evaluated between January 2011 and May 2019. Echocardiograms were performed at a median of 3 days from the time of RHC, with the majority occurring beforehand (76%). Individuals were classified as having low, intermediate, or high probability of PH according to their tricuspid regurgitation velocity (TVR) and the presence of echocardiographic evidence of PH. Echocardiographic criteria for PH included at least 2 of the following: detection of a right/left ventricle basal diameter ratio above 1, interventricular septum flattening, right ventricle outflow doppler acceleration time under 105 m/s, mid-systolic notching, or early diastolic pulmonary regurgitation velocity above 2.2 m/s-1.
A total of 111 patients with severe COPD (defined according to the 6th World Symposium of Pulmonary Hypertension) who received RHC were evaluated. Of these 111, 82 patients were identified with COPD-PH (74%). Overall, patients had a mean PAP (mPAP) of 30.3 mm Hg, systolic PAP (sPAP) of 45.8 mm Hg, diastolic PAP (dPAP) of 21.8 mm Hg, pulmonary vascular resistance (PVR) of 4.0 mm Hg, diastolic pulmonary gradient (DPG) of 8.5 mm Hg, right arterial pressure (RAP) of 9.7 mm Hg, and pulmonary capillary wedge pressure (PCWP) of 13.5 mm Hg. Those with COPD-PH were noted to have significantly higher PAP levels compared to those without.
According to the echocardiographic criteria, 20 patients (18%) had a high likelihood for PH, 20 (18%) had intermediate, and 71 (64%) had low. In these cases, the sensitivity, specificity, positive predictive, and negative predictive values for echocardiography diagnosing COPD-PH were 43%, 83%, 88%, and 34%, respectively. Additionally, for the diagnosis of COPD–severe PH, these values were 67%, 75%, 50%, and 86%.
In light of their findings, the authors note that the echocardiography’s high specificity and positive predictive values demonstrate its value in the diagnosis of COPD-PH; however, it exhibited limited sensitivity for ruling out COPD-PH and its efficacy was impacted by the presence of significant hyperinflation or sever emphysema in these patients. The authors conclude by mentioning their results were not consistent with recommendations for identifying COPD-PH with noninvasive methods for advanced COPD; therefore, pretransplant RHC should still be considered.
Reference
Younis M, Al-Antary N, Dalbah R, et al. Echocardiography and pulmonary hypertension in patients with chronic obstructive pulmonary disease undergoing lung transplantation evaluation. Am J Med Sci. Published online November 13, 2023. doi:10.1016/j.amjms.2023.11.006
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More